You need to enable JavaScript to run this app.
Recon: FDA Approves SK Life Science’s Seizure Drug Xcopri; Rewrite Coming for Grassley-Wyden Drug Pricing Bill
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher